Warning Letter — Auriga Research Pvt. Ltd.
The FDA issued a Warning Letter to Auriga Research Pvt. Ltd. following an evaluation by the Center for Drug Evaluation and Research (CDER). The document reflects regulatory findings from a recent inspection or review of the firm's operations.
This notice affects Auriga Research Pvt. Ltd. and pharmaceutical sponsors utilizing their research or analytical services. It also impacts internal quality and clinical teams responsible for vendor oversight.
The issuance of a Warning Letter to a research organization suggests potential deficiencies in data integrity, clinical trial conduct, or laboratory practices. For sponsors, this may imply that data generated by this facility could be scrutinized during drug application reviews, potentially requiring re-validation or supplemental audits to ensure regulatory acceptance.
Review third-party research and testing service providers for adherence to FDA compliance standards. Ensure quality agreements are robust and that clinical or analytical data generated by external partners undergo rigorous internal verification.
FDA Warning Letter issued to: Auriga Research Pvt. Ltd.. 08/12/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/auriga-research-pvt-ltd-730694-08122026
Open in openFDA / FDA.gov